7216-73-1

Upstream product

• 2914-23-0 barium methoxide 
• 906330-68-5 methyl-[O²,O³,O⁶-triacetyl-O⁴-(tetra-O-acetyl-β-D-glucopyranosyl)-β-D-mannopyranoside] 
• 67-56-1 methanol 
• 14227-66-8 acetobromocellobiose 
• 709-50-2 methyl beta-D-glucopyranoside 
• 59-56-3 α-D-glucopyranosyl-1-phosphate 
• 69308-57-2 Acetic acid (3R,4S,5R,6R)-3-acetoxy-6-acetoxymethyl-2-bromo-5-((2S,3R,4S,5R,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-4-yl ester 
• 30021-60-4 peracetylated methyl β-cellobioside 
• 13360-52-6 Cellobiose 
• 124-41-4 sodium methylate 
• 14218-11-2 2,3,4,6-tetra-O-benzoylglucosyl bromide 
• 19488-48-3 methyl O-2,3,6-tri-O-benzyl-α-D-glucopyranoside 
• 77068-23-6 3,6,2',3',4',6'-hexa-O-acetyl-α-cellobioside 
• 88559-79-9 methyl (β-D-glucopyranosyl)-(1->4)-2,3,6-tri-O-benzyl-α-D-glucopyranoside 

Downstream Products

• 74895-01-5 methyl 4-O-(4,6-O-benzylidene-β-D-glucopyranosyl)-β-D-glucopyranoside 
• 74895-02-6 methyl 2,3,6-tri-O-acetyl-4-O-(2,3-di-O-acetyl-4,6-O-benzylidene-β-D-glucopyranosyl)-β-D-glucopyranoside 
• 64-18-6 formic acid 
• 526-95-4 gluconic acid 
• 156038-69-6 methyl 4,6-O-benzylidene-β-D-glucopyranosyl-(1->4)-β-D-glucopyranoside 
• 155896-89-2 methyl 4‐O‐(2,3‐di‐O‐benzyl‐4,6‐O‐benzylidene‐β‐D‐glucopyranosyl)‐2,3,6‐tri‐O‐benzyl‐β‐D-glucopyranoside 
• 155786-86-0 methyl 2,3,6-tri-O-benzyl-β-D-glucopyranosyl-(1->4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside 
• 423719-29-3 methyl 2,3,6-tri-O-benzyl-4-O-methyl-β-D-glucopyranosyl-(1->4)-2,3,6-tri-O-benzyl-β-D-glucopyranoside 
• 84094-28-0 methyl 4-O-(4-O-benzoyl-2,3,6-trideoxy-β-D-erythro-hexopyranosyl)-2,3,6-trideoxy-β-D-erythro-hexopyranoside 
• 84094-27-9 methyl 4-O-(4,6-O-benzylidene-2,3-dideoxy-β-D-erythro-hexopyranosyl)-2,3,6-trideoxy-β-D-erythro-hexopyranoside 
• 84094-29-1 Benzoic acid (2S,3S,6R)-2-bromomethyl-6-((2R,3S,6R)-6-methoxy-2-methyl-tetrahydro-pyran-3-yloxy)-tetrahydro-pyran-3-yl ester 
• 84094-26-8 methyl 4-O-(4,6-O-benzylidene-2,3-dideoxy-β-D-erythro-hex-2-enopyranosyl)-2,3,6-trideoxy-β-D-erythro-hex-2-enopyranoside 
• 84094-24-6 methyl 4-O-(4,6-O-benzylidene-β-D-glucopyranosyl)-6-deoxy-β-D-glucopyranoside 
• 84094-23-5 methyl 2,3-di-O-acetyl-6-deoxy-4-O-(2,3-di-O-acetyl-4,6-O-benzylidene-β-D-glucopyranosyl)-β-D-glucopyranoside 

Relevant academic research and scientific papers

Characterization of a cellobiose phosphorylase from a hyperthermophilic eubacterium, Thermotoga maritima MSB8

The cepA putative gene encoding a cellobiose phosphorylase of Thermotoga maritima MSB8 was cloned, expressed in Escherichia coli BL21-codonplus-RIL and characterized in detail. The maximal enzyme activity was observed at pH 6.2 and 80°C. The energy of activation was 74 kJ/mol. The enzyme was stable for 30 min at 70°C in the pH range of 6-8. The enzyme phosphorolyzed cellobiose in an random-ordered bi bi mechanism with the random binding of cellobiose and phosphate followed by the ordered release of D-glucose and α-D-glucose-1- phosphate. The Km for cellobiose and phosphate were 0.29 and 0.15 mM respectively, and the kcat was 5.4 s-1. In the synthetic reaction, D-glucose, D-mannose, 2-deoxy-D-glucose, D-glucosamine, D-xylose, and 6-deoxy-D-glucose were found to act as glucosyl acceptors. Methyl-β-D- glucoside also acted as a substrate for the enzyme and is reported here for the first time as a substrate for cellobiose phosphorylases. D-Xylose had the highest (40 s-1) kcat followed by 6-deoxy-D-glucose (17 s-1) and 2-deoxy-D-glucose (16 s-1). The natural substrate, D-glucose with the kcat of 8.0 s-1 had the highest (1.1 × 104 M-1 s-1) k cat/Km compared with other glucosyl acceptors. D-Glucose, a substrate of cellobiose phosphorylase, acted as a competitive inhibitor of the other substrate, α-D-glucose-1-phosphate, at higher concentrations.

COMPOUNDS FOR TREATING AND PREVENTING NET ASSOCIATED COMPLICATIONS

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of NET mediated ailments in subjects.

DITHIOLSACCHARIDE MUCOLYTIC AGENTS AND USES THEREOF

There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES

The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of β-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Na), in the therapy of a range of extracellular histone mediated ailments in subjects.

Metal-catalyzed stereoselective and protecting-group-free synthesis of 1,2-cis-glycosides using 4,6-dimethoxy-1,3,5-triazin-2-yl glycosides as glycosyl donors

4,6-Dimethoxy-1,3,5-triazin-2-yl glycosides, glycosyl donors prepared in one step from free saccharides without protection of the hydroxy groups, were stereoselectively and equivalently converted to the corresponding 1,2-cis-glycosides by using a catalytic amount of metal catalyst. This reaction was successfully applied not only to monosaccharides, but also to di- and oligosaccharides.

Completely β-selective glycosylation using 3,6- O-(o-xylylene)-bridged axial-rich glucosyl fluoride

A completely β-selective glycosylation that does not rely on neighboring group participation is described. The novelty of this work is the design of the glycosyl donor locked into the axial-rich form by the o-xylylene bridge between the 3-O and 6-O of d-glucopyranose. The synthesized 2,4-di-O-benzyl-3,6-O-(o-xylyene)glucopyranosyl fluoride could efficiently react with various alcohols in a SnCl2-AgB(C6F 5)4 catalytic system. The mechanism composed of the glycosylation and isomerization cycles was revealed through comparative experiments using acidic and basic molecular sieves. The achieved perfect stereocontrol is attributed to the synergy of the axial-rich conformation and convergent isomerization caused by HB(C6F5)4 generated in situ.

Synthesis of C7-C16-Alkyl maltosides in the presence of tin(IV) chloride as a lewis acid catalyst

The synthesis of C7- to C16-alkyl maltosides in the presence of tin(IV) chloride as Lewis acid catalyst was performed. The characterization of the products and theoretical investigation of the crucial step in the synthesis were carried out. The preparation of the β-maltosides required reaction time of 1 h, and that of the α-maltosides was 72 h. The side products were the α-D-maltosidechloride and 2-hydroxy-β-maltoside, respectively. The PM3 calculation confirmed the formation of the kinetically controlled β-product.

Studies on the boronation of methyl-β-d-cellobioside-a cellulose model

The conversion of phenylboronic acid (PBA) with methyl-β-d-cellobioside (Me-β-d-clb) and cellodextrins (DPw 12) was investigated to gain a basic understanding of the interactions of boric acid derivatives with oligo- and polyglucans. By means of MS and NMR experiments, it was possible to show a first stage formation of a six-membered ring at C-4 and C-6 of the non-reducing glucose occurs as in the case of monosaccharides. If the amount of reagent is increased the formation of seven-membered rings at the secondary OH moieties is observed. Even the existence of two of these large ring-systems in the direct neighborhood was found. Application of an excess of boronation reagent led to dimerization reactions of Me-β-d-clb via the primary reducing glucose residue as confirmed by DOSY NMR studies. Preliminary 13C NMR studies for the interaction of cellodextrins with PBA in DMSO solution confirmed a functionalization at the trans-1,2-diol moieties of these oligomers. The amount of reagent applied may either was shown to lead to soluble products or to insoluble cross-linked material.

Use Of An Alkyl Glycoside Or Of A Mixture Of At Least Two Alkyl Glycosides As Agent Intended For Inhibiting Microbial Growth, And Compositions Containing It

The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition.

Stereocontrolled glycoside and glycosyl ester synthesis. Neighboring group participation and hydrogenolysis of 3-(2′-benzyloxyphenyl)-3,3- dimethylpropanoates

Equation presented The 2-O[3-(2′-benzyloxyphenyl)-3,3- dimethylpropanoate] and 2-O-[3-(2′-benzyloxy-4′,6′- dimethylphenyl)-3,3-dimethylpropanoate] esters enable the synthesis of a range of β-glucosides and α-mannosides through neighboring participation in excellent yield, and are removed by hydrogenolysis in concert with the cleavage of benzyl esters in the presence of other esters making them particularly well suited to the stereocontrolled synthesis of glycosyl esters.